Led · Series A · Feb 2026

Prenosis develops AI-powered diagnostic and therapeutic tools that tailor care to each patient’s unique biological profile. Its core Immunix platform aggregates deep biological data to create diagnostics such as the Sepsis ImmunoScore, the first FDA-authorized AI test for sepsis. The company aims to commercialize ImmunoScore while continuing to expand its portfolio of biology-based diagnostics. Plans include deploying the platform in up to 40 academic medical centers to establish a precision-medicine clinical-trial network, enabling rapid recruitment of patients with specific biological signatures. Led by CEO Bobby Reddy, Jr., PhD, Prenosis positions itself at the intersection of data science, biology, and clinical practice to improve outcomes in critical conditions. The new capital will accelerate product rollout and broaden clinical integration efforts, supporting the company’s mission to personalize critical-care medicine.

Led · Series A · May 2024

Backpack Healthcare (formerly Youme Healthcare) operates an online pediatric mental-health platform that combines an AI-powered emotion-monitoring app with live teletherapy delivered by licensed clinicians. The company’s algorithms assess mood signals and automatically match young users to therapists who specialize in their needs, creating individualized treatment plans. Beyond one-on-one pediatric sessions, Backpack offers family therapy, medication management, and live parent-training webinars covering topics such as cyberbullying and substance abuse. Interactive digital tools and gamified activities are used to keep children engaged and encourage consistent participation in care. With its newly secured capital, management plans to enhance the technology stack, broaden geographic reach, and deepen its teletherapy service portfolio. Equity and inclusion remain a stated priority, underscored by the addition of Robert Johnson, ESQ, to the advisory board to guide inclusive growth initiatives.

Participated · Series A · Aug 2023

AMOpportunities operates a platform that connects medical students and graduates with physicians to secure clinical experiences and rotations. The company facilitates placements with U.S. hospitals and clinical partners and works with global medical schools. It recently closed an additional $2 million into its Series A2, bringing total funding to nearly $11 million. AMO says it will use the new capital to expand its network of U.S. hospitals and clinical partners as well as global medical schools. Recent company developments include appointing Dr. Kevin Klauer as senior advisor for strategic partnerships, adding Jon David Willingham to the board, and celebrating its 10th anniversary. Leadership reiterated confidence in the company’s progress toward addressing healthcare provider shortages.

Participated · Seed · Oct 2021

Alloy operates a telehealth platform that links women with physicians trained in menopause care, offering clinician community support and annual in-person training for its providers. The company emphasizes capital-efficient growth, claiming near-zero physician attrition and zero recruiting costs because clinicians join organically. Alloy reached profitability around its Series A in November 2024 and has since reinvested earnings into growth rather than hoarding cash. Its leadership, including co‑founders and co‑CEOs Anne Fulenwider and Monica Molenaar, positions the company as deliberately disciplined compared with better‑funded peers. The broader market context cited in reporting notes roughly 1.3 million U.S. women enter menopause each year and a global menopause market valued at about $17.8 billion in 2024. Alloy is pursuing a retention- and unit-economics-driven expansion rather than rapid, capital-intensive scaling.